BR112022005024A2 - Anticorpos anti-nrp1a e seus usos para o tratamento dos olhos ou doenças oculares - Google Patents

Anticorpos anti-nrp1a e seus usos para o tratamento dos olhos ou doenças oculares

Info

Publication number
BR112022005024A2
BR112022005024A2 BR112022005024A BR112022005024A BR112022005024A2 BR 112022005024 A2 BR112022005024 A2 BR 112022005024A2 BR 112022005024 A BR112022005024 A BR 112022005024A BR 112022005024 A BR112022005024 A BR 112022005024A BR 112022005024 A2 BR112022005024 A2 BR 112022005024A2
Authority
BR
Brazil
Prior art keywords
nrp1a
antibodies
eyes
treatment
eye diseases
Prior art date
Application number
BR112022005024A
Other languages
English (en)
Inventor
Fei Han
Juergen Prestle
Leo Thomas
Nina Zippel
Pankaj Gupta
Sarah Low
Yining Huang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112022005024A2 publication Critical patent/BR112022005024A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos anti-nrp1a e seus usos para o tratamento dos olhos ou doenças oculares. a presente invenção refere-se a anticorpos e fragmentos dos mesmos que se direcionam ao domínio a de neuropilina-1 (nrp1a). mais especificamente, os anticorpos anti-nrp1a e os métodos de uso para o trata-mento de várias doenças ou distúrbios são descritos.
BR112022005024A 2019-09-24 2020-09-24 Anticorpos anti-nrp1a e seus usos para o tratamento dos olhos ou doenças oculares BR112022005024A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19199099 2019-09-24
EP20150942 2020-01-09
PCT/EP2020/076685 WO2021058636A1 (en) 2019-09-24 2020-09-24 Anti-nrp1a antibodies and their uses for treating eye or ocular diseases

Publications (1)

Publication Number Publication Date
BR112022005024A2 true BR112022005024A2 (pt) 2022-06-21

Family

ID=72752879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005024A BR112022005024A2 (pt) 2019-09-24 2020-09-24 Anticorpos anti-nrp1a e seus usos para o tratamento dos olhos ou doenças oculares

Country Status (16)

Country Link
US (2) US11661458B2 (pt)
EP (1) EP4034161A1 (pt)
JP (1) JP2022549005A (pt)
KR (1) KR20220069076A (pt)
CN (1) CN114423788A (pt)
AU (1) AU2020355599A1 (pt)
BR (1) BR112022005024A2 (pt)
CA (1) CA3154654A1 (pt)
CO (1) CO2022003324A2 (pt)
CR (1) CR20220122A (pt)
IL (1) IL291522A (pt)
JO (1) JOP20220074A1 (pt)
MX (1) MX2022003544A (pt)
PE (1) PE20221315A1 (pt)
TW (1) TW202126685A (pt)
WO (1) WO2021058636A1 (pt)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
AU2011253904B2 (en) * 2005-11-08 2014-02-13 Genentech, Inc. Neuropilin antagonists
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AU2007353779B2 (en) 2007-05-17 2013-11-07 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
AU2014221144B2 (en) 2013-02-21 2018-03-22 Rsem, Limited Partnership Inhibition of Sema3A in the prevention and treatment of ocular hyperpermeability
SI3189074T1 (sl) * 2014-09-05 2021-08-31 Rsem, Limited Partnership Sestavki in postopki za zdravljenje in preprečevanje vnetja
CA2969402C (en) * 2014-12-03 2019-06-11 Samsung Life Public Welfare Foundation Antibody binding to neuropilin 1 and use thereof
JOP20190134A1 (ar) * 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها

Also Published As

Publication number Publication date
CN114423788A (zh) 2022-04-29
US20230416378A1 (en) 2023-12-28
PE20221315A1 (es) 2022-09-07
CR20220122A (es) 2022-05-05
KR20220069076A (ko) 2022-05-26
CO2022003324A2 (es) 2022-04-19
MX2022003544A (es) 2022-04-11
US20210087282A1 (en) 2021-03-25
EP4034161A1 (en) 2022-08-03
US11661458B2 (en) 2023-05-30
TW202126685A (zh) 2021-07-16
AU2020355599A1 (en) 2022-04-07
IL291522A (en) 2022-05-01
CA3154654A1 (en) 2021-04-01
WO2021058636A1 (en) 2021-04-01
JP2022549005A (ja) 2022-11-22
JOP20220074A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
BR112021019854A2 (pt) Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112018067721A2 (pt) anticorpos específicos para tau hiperfosforilada para o tratamento de doenças oculares
BR112018070357A2 (pt) anticorpos anticomplemento contra o fator bb e seus usos
EA202191764A1 (ru) Замещенные оксопиридиновые производные
BR112022014949A2 (pt) Compostos e usos dos mesmos
BR112018012927A2 (pt) reguladores cftr e métodos de uso dos mesmos
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
BR112022015110A2 (pt) Compostos e usos dos mesmos
WO2020021480A3 (en) Compositions and methods for treating the eye
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BR112017020610A2 (pt) Compostos de anticorpo biespecífico anti-dkk-1- anti-rankl
BR112018012949A2 (pt) reguladores cftr e métodos de uso dos mesmos
BR112018012934A2 (pt) reguladores cftr e métodos de uso dos mesmos
BR112022005024A2 (pt) Anticorpos anti-nrp1a e seus usos para o tratamento dos olhos ou doenças oculares